The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.
The two organizations are collaborating to perform a standardized evaluation of currently available molecular diagnostic tests to assess test performance.
The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.
FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
